Text Size Normal Text Sizing Button Medium Text Sizing Button Large Text Sizing Button Text Contrast Normal Contrast Button Reverse Contrast Button Switch to Spanish Language Press Room Contact Us Sitemap Sign In Register
Link to Homepage About BrightFocus
Donate Now Get Involved  
Alzheimer's Disease Research Macular Degeneration Research National Glaucoma Research

Stay Informed: Medical and Research Updates
Connect With Us!


Specialized Nanofiber Destined For Glaucoma Treatment

August 30, 2010

Adapted from the University of Dayton Research Institute

A “smart” nanomaterial recently developed at the University of Dayton Research Institute for multi-purpose use in aircraft coatings, wind turbines and other large-scale commercial applications may also lead to a significant breakthrough in glaucoma treatment. Nicknamed “fuzzy fiber” by inventor Khalid Lafdi, distinguished research engineer at UDRI, the tailored carbon material is expected to improve the lives of glaucoma sufferers by reducing the number of medical procedures needed to treat the disease.

The new technology will be used to create biocompatible, non-clogging drainage tubes to relieve excess fluid and pressure in the eye. The carbon tubes will be marketed as an alternative to silicone tubes, which must be replaced over time in most patients because they become encapsulated with naturally occurring growth cells called fibroblasts, inhibiting their ability to drain fluid. Successful animal testing will pave the way for FDA approval for clinical trials in humans; the inventors expect the new tubes to be on the market within three years.

The research was sponsored by Mobius Therapeutics in St. Louis, owned and operated by University of Dayton graduate Ed Timm. Mobius supports research and development for advances in treatment for glaucoma.

“Glaucoma is frequently called the 'sneak thief of sight' because damage occurs slowly, and there are no symptoms until vision starts to become lost,” Timm said. “Once damage is done, that vision loss cannot be reversed.”

Because prevention is the “absolute best treatment,” annual eye exams that include a simple test for glaucoma are critical to helping prevent blindness, Timm said. “If glaucoma is detected, typically the first line of therapy is in the form of pharmaceuticals—drugs that help maintain proper IOP. If drugs are not appropriate or are no longer working, the next line of treatment involves using a laser to create a hole in the eye for fluid drainage. But the body responds by producing fibroblasts, a kind of scar tissue that can close up the hole and cause additional problems.”

When surgical intervention is warranted, a silicone shunt is implanted in the eye to facilitate drainage. Silicone is highly biocompatible, which is also its downfall, Timm said. “Silicone is not just the wrong material to use, it is exactly the wrong material. Because the body does not see it as a foreign material, the tube immediately becomes encapsulated with fibroblasts as healing takes place around it. As scar tissue builds up over time, the tube can no longer drain fluid and must be replaced.”

Lafdi and Timm designed a drain tube using Lafdi's “fuzzy fiber,” a scaffold of carbon—also highly biocompatible – covered with surface-treated carbon nanotubes grown in a highly controlled manner, giving the material its fuzzy appearance. Those chemically modified nanotubes prevent the formation and build-up of fibroblasts, Lafdi said. “Multiple tests demonstrated that, in the presence of tailored carbon nanotubes, there was zero cell growth. But when I coated the same carbon scaffold with silicone, there was cell proliferation. An absolute invasion.”

Timm said use of the material in glaucoma treatment is revolutionary. “There's nothing else like it out there. Not only is the material completely biocompatible, eliminating the risk for rejection by the body, it will also serve to preserve the longevity of the implant by keeping it from becoming blocked with tissue. I believe this will completely change the thought process in the design of future ophthalmic devices.”

The patent application for the technology covers applications for ear drainage tubes in addition to ophthalmic use, said Lafdi, who is also a faculty member in the University's School of Engineering.

View all news updates for glaucoma

Disclaimer: The information provided in this section is a public service of the BrightFocus Foundation, and should not in any way substitute for the advice of a qualified healthcare professional, and is not intended to constitute medical advice. Although we take efforts to keep the medical information on our website updated, we cannot guarantee that the information on our website reflects the most up-to-date research. Please consult your physician for personalized medical advice; all medications and supplements should only be taken under medical supervision. BrightFocus Foundation does not endorse any medical product or therapy.

Some of the content in this section is adapted from other sources, which are clearly identified within each individual item of information.

YouTube Twitter YouTube Shop for a Cause Connect With Us Pinterest Google+